×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIK – anika therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
03:56 am
anik
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference [Yahoo! Finance]
Low
Report
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference [Yahoo! Finance]
2/27
04:25 pm
anik
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
Low
Report
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
2/26
11:26 am
anik
Anika Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Anika Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
07:32 am
anik
Anika Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Anika Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
07:05 am
anik
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
2/18
04:01 pm
anik
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Low
Report
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
2/12
04:01 pm
anik
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Low
Report
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
2/4
09:27 am
anik
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors [Yahoo! Finance]
Medium
Report
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
06:02 am
anik
Form 10-K Anika Therapeutics, Inc. For: Dec 31
Low
Report
Form 10-K Anika Therapeutics, Inc. For: Dec 31
2/26
07:18 am
anik
Form 8-K Anika Therapeutics, Inc. For: Feb 26
Medium
Report
Form 8-K Anika Therapeutics, Inc. For: Feb 26
2/3
06:46 pm
anik
Form 4 Anika Therapeutics, Inc. For: Feb 01 Filed by: Griffin Stephen D.
Medium
Report
Form 4 Anika Therapeutics, Inc. For: Feb 01 Filed by: Griffin Stephen D.
1/27
07:29 pm
anik
Form SCHEDULE 13D/A Anika Therapeutics, Inc. Filed by: Caligan Partners LP
Low
Report
Form SCHEDULE 13D/A Anika Therapeutics, Inc. Filed by: Caligan Partners LP
1/8
04:03 pm
anik
Form 8-K Anika Therapeutics, Inc. For: Jan 07
Low
Report
Form 8-K Anika Therapeutics, Inc. For: Jan 07
1/8
03:00 pm
anik
Form SCHEDULE 13G/A Anika Therapeutics, Inc. Filed by: Trigran Investments, Inc.
Low
Report
Form SCHEDULE 13G/A Anika Therapeutics, Inc. Filed by: Trigran Investments, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/24
Q3/2019 9/30/2019 EPS 0.640 ZacksConsensus 0.410 ActVsEst 0.230 - Beat
35.2%
7/24 Q2/2019 6/30/2019 EPS 0.670 ZacksConsensus 0.420 ActVsEst 0.250 - Beat 29.0%
4/8 Anika Therapeutics beefs up liquidity amid COVID-19 disruptions [Seeking Alpha] 9.0%
3/24 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 8.9%
4/28 Form 4 Anika Therapeutics, Inc. For: Apr 26 Filed by: Blanchard Cheryl R 7.9%
5/3 Anika Therapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] 5.9%
1/6 Anika Therapeutics to Acquire Parcus Medical and Arthrosurface 4.6%
4/22 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.6%
4/27 Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer 4.3%
7/25 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock. 3.2%
7/24 Q2/2019 6/30/2019 EPS 0.670 ZacksConsensus 0.420 ActVsEst 0.250 - Beat 29.0%
4/8 Anika Therapeutics beefs up liquidity amid COVID-19 disruptions [Seeking Alpha] 9.0%
3/24 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 8.9%
4/28 Form 4 Anika Therapeutics, Inc. For: Apr 26 Filed by: Blanchard Cheryl R 7.9%
5/3 Anika Therapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] 5.9%
1/6 Anika Therapeutics to Acquire Parcus Medical and Arthrosurface 4.6%
4/22 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.6%
4/27 Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer 4.3%
7/25 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock. 3.2%
TOP News Decliners
3/13
Form 8-K/A Anika Therapeutics, Inc. For: Feb 03
-16.2%
3/18 Form SEC STAFF LETTER Anika Therapeutics, Inc. -11.5%
3/6 Form 3 Anika Therapeutics, Inc. For: Mar 04 Filed by: Colleran David -9.4%
4/29 Form DEF 14A Anika Therapeutics, Inc. For: Jun 16 -7.3%
2/20 Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.0%
3/17 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.8%
1/29 Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer -5.4%
4/27 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock. -4.7%
7/26 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.5%
7/30 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.4%
3/18 Form SEC STAFF LETTER Anika Therapeutics, Inc. -11.5%
3/6 Form 3 Anika Therapeutics, Inc. For: Mar 04 Filed by: Colleran David -9.4%
4/29 Form DEF 14A Anika Therapeutics, Inc. For: Jun 16 -7.3%
2/20 Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.0%
3/17 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.8%
1/29 Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer -5.4%
4/27 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock. -4.7%
7/26 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.5%
7/30 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: